Tapentadol Prolonged Release in Patients with Chronic low back Pain: Real-World Data from the German Pain eRegistry

References

• GBD 2017 Disease and Injury Incidence and Prevalence Collaborators . Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet392, 1789–1858 (2018).
   PubMed Web of Science ®Google Scholar
• Hartvigsen J , HancockMJ , KongstedAet al. Low back pain 1. What low back pain is and why we need to pay attention. Lancet391, 2356–2367 (2018).
   PubMed Web of Science ®Google Scholar
• Itz CJ , GeurtsJW , van KleefM , NelemansP. Clinical course of non-specific low back pain: a systematic review of prospective cohort studies set in primary care. Eur. J. Pain.17, 5–15 (2013).
   PubMed Web of Science ®Google Scholar
• Freynhagen R , BaronR. The evaluation of neuropathic components in low back pain. Curr. Pain Headache Rep.13, 185–190 (2009).
   PubMed Web of Science ®Google Scholar
• Morlion B . Chronic low back pain: pharmacological, interventional and surgical strategies. Nat. Rev. Neurol.9, 462–473 (2013).
   PubMed Web of Science ®Google Scholar
• Baron R , BinderA , AttalN , CasaleR , DickensonAH , TreedeRD. Neuropathic low back pain in clinical practice. Eur. J. Pain.20, 861–873 (2016).
   PubMed Web of Science ®Google Scholar
• Foster NE , AnemaJR , CherkinDet al. Low back pain 2. Prevention and treatment of low back pain: evidence, challenges, and promising directions. Lancet391, 2368–2383 (2018).
   PubMed Web of Science ®Google Scholar
• Oliveira CB , MaherCG , PintoRZet al. Clinical practice guidelines for the management of non-specific low back pain in primary care: an updated overview. Eur. Spine J.27, 2791–2803 (2018).
   PubMed Web of Science ®Google Scholar
• O’Brien T , ChristrupLL , DrewesAMet al. European Pain Federation position paper on appropriate opioid use in chronic pain management. Eur J Pain.21, 3–19 (2017).
   PubMed Web of Science ®Google Scholar
• Benyamin R , TrescotAM , DattaSet al. Opioid complications and side effects. Pain Physician.11, S105–S120 (2008).
   PubMed Web of Science ®Google Scholar
• Panchal SJ , Müller-SchwefeP , WurzelmannJI. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int. J. Clin. Pract.61, 1181–1187 (2007).
   PubMed Web of Science ®Google Scholar
• Farmer AD , DrewesAM , ChiarioniGet al. Pathophysiology and management of opioid-induced constipation: European Expert Consensus statement. United European Gastroenterol. J.7, 7–20 (2019).
   PubMed Web of Science ®Google Scholar
• Lee AA , HaslerWL. Opioids and GI motility – friend or foe?Curr. Treat. Options Gastroenterol.14, 478–494 (2016).
   PubMedGoogle Scholar
• Tzschentke TM , ChristophT , KögelBY. The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol. CNS Drugs.28, 319–329 (2014).
   PubMed Web of Science ®Google Scholar
• Baron R , EberhartL , KernKUet al. Tapentadol prolonged release for chronic pain: a review of clinical trials and 5 years of routine clinical practice data. Pain Pract.17, 678–700 (2017).
   PubMed Web of Science ®Google Scholar
• Buynak R , ShapiroDY , OkamotoAet al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. Expert Opin. Pharmacother.11, 1787–1804 (2010).
   PubMed Web of Science ®Google Scholar
• Steigerwald I , MüllerM , DaviesAet al. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, Phase 3b study. Curr. Med. Res. Opin.28, 911–936 (2012).
   PubMed Web of Science ®Google Scholar
• Gálvez R , SchäferM , HansG , FalkeD , SteigerwaldI. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, Phase 3b study. Adv. Ther.30, 229–259 (2013).
   PubMed Web of Science ®Google Scholar
• Baron R , LikarR , Martin-MolaEet al. Effectiveness of tapentadol prolonged release (PR) compared with oxycodone/naloxone PR for the management of severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, Phase 3b/4 study. Pain Pract.16, 580–599 (2016).
   PubMed Web of Science ®Google Scholar
• Baron R , JansenJP , BinderAet al. Tolerability, safety, and quality of life with tapentadol prolonged release (PR) compared with oxycodone/naloxone PR in patients with severe chronic low back pain with a neuropathic component: a randomized, controlled, open-label, Phase 3b/4 trial. Pain Pract.16, 600–619 (2016).
   PubMed Web of Science ®Google Scholar
• Meng Z , YuJ , AcuffMet al. Tolerability of opioid analgesia for chronic pain: a network meta-analysis. Sci. Rep.7, 1995 (2017).
   PubMed Web of Science ®Google Scholar
• Wild JE , GrondS , KuperwasserBet al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract.10, 416–427 (2010).
   PubMed Web of Science ®Google Scholar
• Strick V . Management of severe chronic pain with tapentadol prolonged release - long-term data from pain specialists. Curr. Med. Res. Opin.30, 2085–2092 (2014).
   PubMed Web of Science ®Google Scholar
• Buynak R , RappaportSA , RodKet al. Long-term safety and efficacy of tapentadol extended release following up to 2 years of treatment in patients with moderate to severe, chronic pain: results of an open-label extension trial. Clin. Ther.37, 2420–2438 (2015).
   PubMed Web of Science ®Google Scholar
• Finco G , MuraP , MusuMet al. Long-term, prolonged-release oral tapentadol for the treatment of refractory chronic low back pain: a single-center, observational study. Minerva Medica.109, 259–265 (2018).
   PubMed Web of Science ®Google Scholar
• Gálvez Mateos R , SamperBernal D , TorresMorera LM , FerriCM , EsquiviasEscobar A. Long-term effectiveness and tolerability of pain treatment with tapentadol prolonged release. Pain Physician.24, E75–E85 (2021).
   PubMed Web of Science ®Google Scholar
• Cave A , KurzX , ArlettP. Real-world data for regulatory decision making: challenges and possible solutions for Europe. Clin. Pharm. Ther.106, 36–39 (2019).
   PubMed Web of Science ®Google Scholar
• Bolislis WR , FayM , KühlerTC. Use of real-world data for new drug applications and line extensions. Clin. Ther.42, 926–938 (2020).
   PubMed Web of Science ®Google Scholar
• German Pain Association . Manual for the German Pain Questionnaire (in German). https://www.schmerzgesellschaft.de/fileadmin/pdf/DSF_Handbuch_2020.pdf
   Google Scholar
• Tait RC , ChibnallJT , KrauseS. The pain disability index: psychometric properties. Pain40, 171–182 (1990).
   PubMed Web of Science ®Google Scholar
• Ware J Jr , KosinskiM , KellerSD. A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med. Care34, 220–233 (1996).
   PubMed Web of Science ®Google Scholar
• Freynhagen R , BaronR , GockelU , TölleTR. PainDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr. Med. Res. Opin.22, 1911–1920 (2006).
   PubMed Web of Science ®Google Scholar
• Cappelleri JC , BienenEJ , KoduruV , SadoskyA. Measurement properties of painDETECT by average pain severity. Clinicoecon. Outcomes Res.6, 497–504 (2014).
   PubMedGoogle Scholar
• Rentz AM , YuR , Müller-LissnerS , LeyendeckerP. Validation of the bowel function index to detect clinically meaningful changes in opioid-induced constipation. J. Med. Econ.12, 371–383 (2009).
   PubMedGoogle Scholar
• Ueberall MA , Müller-LissnerS , Buschmann-KrammC , BosseB. The bowel function index for evaluating constipation in pain patients: definition of a reference range for a non-constipated population of pain patients. J. Int. Med. Res.39, 41–50 (2011).
   PubMed Web of Science ®Google Scholar
• von Korff M , OrmelJ , KeefeFJ , DworkinSF. Grading the severity of chronic pain. Pain50, 133–149 (1992).
   PubMed Web of Science ®Google Scholar
• Ostelo RWJG , de VetHCW. Clinically important outcomes in low back pain. Best Pract. Res. Clin. Rheumatol.19, 593–607 (2005).
   PubMed Web of Science ®Google Scholar
• Díaz-Arribas MJ , Fernández-SerranoM , RoyuelaAet al. Minimally clinically important difference in quality of life for patients with low back pain. Spine42, 1908–1916 (2017).
   PubMed Web of Science ®Google Scholar
• Schmitt N , GerbershagenHU. The Mainz Staging System (MPSS) for chronic pain. Pain41(Suppl. 5), S484 (1990).
   Google Scholar
• Überall MA . Poster presentation at the IASP 2021 Virtual World Congress on Pain: opioid-induced constipation in low back pain routine care with tapentadol.. The International Association for the Study of Pain.
   Google Scholar
• Schröder W , DeVry J , TzschentkeTM , JahnelU , ChristophT. Differential contribution of opioid and nonadrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. Eur. J. Pain14, 814–821 (2010).
   PubMed Web of Science ®Google Scholar
• Gonçalves L , FriendLV , DickensonAH. The influence of µ-opioid and noradrenaline reuptake inhibition in the modulation of pain responsive neurones in the central amygdala by tapentadol in rats with neuropathy. Eur. J. Pharmacol.749, 151–160 (2015).
   PubMed Web of Science ®Google Scholar
• Müller-Schwefe GHH , ÜberallMA. Pain and quality of life (in German). Gesundh Ökon. Qual. Manag.16, S20–S22 (2011).
   Google Scholar
• Raffa RB , EllingC , TzschentkeTM. Does ‘strong analgesic’ equal ‘strong opioid’? Tapentadol and the concept of ‘μ-load’. Adv. Ther.35, 1471–1484 (2018).
   PubMed Web of Science ®Google Scholar
• Santos J , AlarcãoJ , FareleiraF , Vaz-CarneiroA , CostaJ. Tapentadol for chronic musculoskeletal pain in adults. Cochrane Database Syst. Rev. 20155, CD009923 (2015).
   Google Scholar
• German Pain Association . Practice guideline opioid-induced constipation (in German) (2019). https://www.dgs-praxisleitlinien.de/index.php/leitlinien/oic
   Google Scholar
• Treede RD , RiefW , BarkeAet al. Chronic pain as a symptom or a disease: the IASP classification of chronic pain for the International Classification of Diseases (ICD-11). Pain160, 19–27 (2019).
   PubMed Web of Science ®Google Scholar
• Krenz P , WulfsbergJP , BruhnsF-L. Unfold Collective Intelligence! - opening up new potentials of value creation (in German). ZWF Zeitschrift für Wirtschaftlichen Fabrikbetrieb107(3), 152–157 (2012).
   Google Scholar